Dendritic cell tumor injection (DCTI) therapy
OwnerKenichiro Hasumiinventor
Life of this patent
Estimating the term…
Abstract
The invention relates to a method of treating tumor cells within a patient wherein immature dendritic cells developed from the patient's monocyte cells and an adjuvant are introduced into the patient directly into the patient's tumor cells. The immature dendritic cells and adjuvant combine with the antigens in the tumor cells to form a cancer vaccine, thereby immediately treating the tumor cells of the patient. The invention also provides a precursor treatment step of treating the patient with a radiation therapy or chemotherapy regimen.
Claims33
A method of reduction of tumor cells in tumor tissue of a patient comprising the steps of:
- collecting monocyte cells from the patient,
- culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells,
- introducing the immature dendritic cells into the tumor tissue of the patient, and
- introducing an adjuvant into the tumor tissue of the patient.
A method of reduction of tumor cells in tumor tissue comprising the steps of:
- treating a tumor of a patient with a chemotherapy regimen,
- collecting monocyte cells from the patient,
- culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells,
- introducing the immature dendritic cells into the tumor tissue of the patient, and
- introducing an adjuvant into the tumor tissue of the patient.
A method of reduction of tumor cells in tumor tissue comprising the steps of:
- treating a tumor of a patient with a radiation therapy regimen,
- collecting monocyte cells from the patient,
- culturing the monocyte cells with one or a plurality of factors to form immature dendritic cells from the monocyte cells,
- introducing the immature dendritic cells into the tumor tissue of the patient, and
- introducing an adjuvant into the tumor tissue of the patient.
A cancer vaccine precursor which when introduced into tumor tissue combines with an antigen for the reduction of a tumor in a patient comprising:
- immature dendritic cells derived from monocytes collected from the patient,
- an adjuvant, and
- antigens from the tumor in the patient.
Dependencies are inferred from the claim text.